Please assess the completion status of the following clinical trial:

Trial Title: Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed Schizophrenia (WHO ICD 10)~* Treatment stable (no regulation in medicine for 6 weeks prior)~* Mono antipsychotic treatment~* No regular Antidepressants (PN accepted)~* No regular Benzodiazepines (PN accepted)~Exclusion Criteria:~* Dependence syndrome~* Severe physical illness~* MRI incompatible, non removable objects above shoulders

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Papaverine (Type: EXPERIMENTAL): Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).